Troy Pearson
Overview
Explore the profile of Troy Pearson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
83
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xie X, Manai M, Rampa D, Fuson J, Nakasone E, Pearson T, et al.
Mol Cancer Ther
. 2024 Nov;
PMID: 39588561
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Among TNBC subtypes, the luminal androgen receptor (LAR) subtype expresses high levels of androgen receptor (AR) and generally responds...
2.
Wang X, Semba T, Manyam G, Wang J, Shao S, Bertucci F, et al.
Sci Adv
. 2022 Dec;
8(50):eabn7983.
PMID: 36525493
Inflammatory breast cancer (IBC), the most aggressive breast cancer subtype, is driven by an immunosuppressive tumor microenvironment (TME). Current treatments for IBC have limited efficacy. In a clinical trial (NCT01036087),...
3.
Su F, Wang X, Pearson T, Lee J, Krishnamurthy S, Ueno N, et al.
Mol Ther Oncolytics
. 2022 Jun;
25:305-306.
PMID: 35663226
[This corrects the article DOI: 10.1016/j.omto.2020.08.012.].
4.
Lim B, Peterson C, Davis A, Cho E, Pearson T, Liu H, et al.
Biomedicines
. 2021 Oct;
9(10).
PMID: 34680527
Triple-negative breast cancer (TNBC) is a heterogeneous group of estrogen, progesterone, and HER2-negative breast cancers with poor clinical outcomes. The imipridone ONC201 is a G-protein-coupled dopamine receptor D2 modulator and...
5.
Lee J, Liu H, Pearson T, Iwase T, Fuson J, Lalani A, et al.
Biomedicines
. 2021 Jul;
9(7).
PMID: 34203351
Human epidermal growth factor receptor (EGFR) 2 (HER2) is overexpressed/amplified in about 25% of all breast cancers, and EGFR is overexpressed in up to 76% and amplified in up to...
6.
Xie X, Lee J, Liu H, Pearson T, Lu A, Tripathy D, et al.
Mol Cancer Ther
. 2020 Dec;
20(2):296-306.
PMID: 33323457
Triple-negative breast cancer (TNBC) is the most aggressive subgroup of breast cancer, and patients with TNBC have few therapeutic options. Apoptosis resistance is a hallmark of human cancer, and apoptosis...
7.
Su F, Wang X, Pearson T, Lee J, Krishnamurthy S, Ueno N, et al.
Mol Ther Oncolytics
. 2020 Sep;
18:579-586.
PMID: 32995482
Adipose stromal cells (ASCs) recruited by tumors contribute to the population of cancer-associated fibroblasts. ASCs have been reported to induce tumor growth and chemotherapy resistance. The effect of ASCs on...
8.
Fernandez J, Eckhardt B, Lee J, Lim B, Pearson T, Seitz R, et al.
PLoS One
. 2020 May;
15(4):e0231953.
PMID: 32353087
The original algorithm that classified triple-negative breast cancer (TNBC) into six subtypes has recently been revised. The revised algorithm (TNBCtype-IM) classifies TNBC into five subtypes and a modifier based on...
9.
Lee J, Lim B, Pearson T, Choi K, Fuson J, Bartholomeusz C, et al.
Breast Cancer Res Treat
. 2019 Apr;
176(1):251.
PMID: 30982934
Unfortunately in the original publication of the article, the author's funding support has been mentioned incorrectly. The correct funding statement should read as "This work was supported by the Morgan...
10.
Lee J, Lim B, Pearson T, Choi K, Fuson J, Bartholomeusz C, et al.
Breast Cancer Res Treat
. 2019 Mar;
175(2):339-351.
PMID: 30826934
Purpose: Triple-negative breast cancer (TNBC) lacks the receptor targets estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, and thus, it does not respond to receptor-targeted treatments. TNBC...